Optimizing urinary tract infection outcomes: nitrofurantoin versus fluoroquinolones
Abstract
The rising global prevalence of urinary tract infections and escalating antimicrobial resistance present a critical clinical challenge. Therefore, it is of interest to evaluate the clinical cure rates while minimizing adverse drug reactions (ADRs) and resistance, researchers studied 40 adult patients (80% female) divided into Group I (Nitrofurantoin) and Group II (Fluoroquinolones). Nitrofurantoin achieved a higher clinical cure rate (95%) with 4.75 times greater odds of success than fluoroquinolones (80%). The adverse reaction rate was significantly lower for nitrofurantoin (10% versus 26.7%), though both groups reported similar side effects. Thus, data shows the nitrofurantoin also maintained a lower failure rate (5% versus 15%), supporting its prioritization as a first-line empirical therapy.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.